Repligen | RGEN - Gross Profit On Sales


Repligen reported $110.04M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Align Technology USD 757.43M 20.84M Jun/2026
Bio Techne USD 208.29M 17.01M Mar/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Bruker USD 416M 36.2M Jun/2026
Charles River Laboratories USD 348.78M 69.47M Jun/2026
Danaher USD 3.61B 20M Jun/2026
Dentsply International USD 493M 66M Jun/2026
General Electric Aerospace USD 4.46B 220M Jun/2026
Henry Schein USD 1.03B 39M Jun/2026
Illumina USD 770M 49M Jun/2026
IQVIA Holdings USD 1.44B 368M Jun/2026
Mettler Toledo International USD 555.82M 119.62M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
OraSure Technologies USD 11.34M 435K Dec/2025
Pacific Biosciences Of California USD 15.74M 601K Dec/2025
Pfizer USD -248M 11.29B Jun/2026
Repligen USD 110.04M 1.75M Jun/2026
Revvity USD 416.87M 29.21M Jun/2026
Standard Biotools USD 11.31M 74K Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Waters USD 490M 52M Jun/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026